BUSINESSWEEK ONLINE : JUNE 12, 2000 ISSUE
COVER STORY Genomics among the Giants While the payoff may be years away, Big Pharma is racing to build its genomics expertise. GLAXO SMITHKLINE * SmithKline was early to genomics with its 1993 deal to gain access to Human Genome Sciences data. Glaxo is working to identify genes that make people susceptible to diseases like asthma. PFIZER INC. ** Pfizer has struck external alliances, including a November, 1999, deal with gene-sequencing company Celera. The two companies will work together to identify drug targets from Celera's massive genomic database. MERCK & CO. The company has struck deals with companies such as DNA chipmaker Affymetrix to access new technology. Merck is relying largely on public information and its own gene sleuths to uncover new drug targets. BRISTOL-MYERS SQUIBB It has struck more than a dozen alliances in three years. A big player in cancer drugs, Bristol is collecting tumor samples and patient DNA to explain why drugs do or don't work against certain cancers. * MERGER OF GLAXO WELLCOME AND SMITHKLINE BEECHAM EXPECTED TO CLOSE THIS SUMMER. ** MERGER OF PFIZER AND WARNER-LAMBERT IS EXPECTED TO CLOSE EARLY JUNE. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ BACK TO TOP					RELATED ITEMS The Genome Gold Rush COVER IMAGE: Eureka! The Genome Gold Rush TABLE: Unearthing DNA's Riches The Genome Explained What This Means to You The Pharma Frenzy TABLE: Genomics among the Giants Survival of...Who? CHART: The Biotech Roller Coaster ONLINE ORIGINAL: William Haseltine on Human Genome Science's Plan ONLINE ORIGINAL: The Slow, Painful Path to Payday in Genomic Stocks INTERACT E-Mail to Business Week Online

Copyright 2000-2008, by The McGraw-Hill Companies Inc. All rights reserved. Terms of Use   Privacy Notice